WEP Clinical Revenue and Competitors

Location

#6847

Growjo Ranking

Pharma

Industry

Estimated Revenue & Valuation

  • WEP Clinical's estimated annual revenue is currently $36.8M per year.(i)
  • WEP Clinical's estimated revenue per employee is $201,000

Employee Data

  • WEP Clinical has 183 Employees.(i)
  • WEP Clinical grew their employee count by 33% last year.

WEP Clinical's People

NameTitleEmail/Phone
1
Chief Operating OfficerReveal Email/Phone
2
VP and Global Head, Data and Safety ServicesReveal Email/Phone
3
VP, Business Development, Expanded Access ProgramsReveal Email/Phone
4
VP, Head Regulatory AffairsReveal Email/Phone
5
Controller at WEP ClinicalReveal Email/Phone
6
VP Strategic AlliancesReveal Email/Phone
7
VP, Project ManagementReveal Email/Phone
8
Associate Director, Quality AssuranceReveal Email/Phone
9
Associate Director, QA, RP & RPiReveal Email/Phone
10
Director Project ManagementReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$5.8M294%N/AN/A
#2
$3.2M160%N/AN/A
#3
$83.2M4147%N/AN/A
#4
$31M15456%N/AN/A
#5
$66.6M2650%$35MN/A
#6
$10.9M546%N/AN/A
#7
$6.8M34-6%N/AN/A
#8
$165.7M21614%$250.7MN/A
#9
$26.5M132-11%$637.8KN/A
#10
$49.4M2466%N/AN/A
Add Company

What Is WEP Clinical?

We are a rapidly growing niche pharmaceutical services company operating in four key sectors:- Managed Access Programs (MAP) Unlicensed Medicines Access Clinical Trial Sourcing Reference Product Supply. Our goal is to provide positive measurable outcomes to patients and sponsors but above all else we want to be known as your trusted partner and an extension of your team. UK headquarters established in London in 2008. US Headquarters established in Research Triangle Park, North Carolina in 2012. Our team has many years of pharmaceutical, clinical and regulatory experience gained in companies such as Pfizer, AZ, MSD, GSK, UDG Healthcare, Waymade, Sanofi, Quintiles & Walgreens Boots Alliance. Our facilities have been inspected & licensed by the MHRA, UK Home Office, FDA and all necessary local approval bodies. We are also approved to handle and distribute controlled substances. We are compliant with all relevant GMDP regulations and operate to a high standard of medicines supply. We operate under a comprehensive Quality Management System with robust and compliant standard operating procedures (SOPs) and policies. Our customers and partners include Pharma, Biotechs, Generic and Biosimilar Developers, CROs and Healthcare and Hospital authorities. We are fully committed to a culture of continual development and strive to service our partners needs beyond their expectations We would be happy to answer any questions that you may have regarding WEP Clinical and our products and services.

keywords:N/A

N/A

Total Funding

183

Number of Employees

$36.8M

Revenue (est)

33%

Employee Growth %

N/A

Valuation

N/A

Accelerator

WEP Clinical News

2022-04-06 - Medlab Clinical set to export first CBD product into the UK market

“Our partners WEP Clinical in the UK have all licenses in place to distribute and supply under the UK Named Patient Program (NPP,) which in...

2022-03-30 - WEP Clinical Appoints Karl Challender as Chief Operating ...

Prior to joining WEP, Karl worked with organisations including Novartis, Alcon, and most recently Worldwide Clinical Trials, where he was...

2019-05-06 - Affera's Technology For Cardiac Arrhythmia Treatment To Be ...

"In the initial clinical experience treating Atrial Fibrillation, the system shows ... Characterization" by Ayelet Shapira-Daniels, MD (S-WEP-03)

2019-03-29 - 31 Stocks Moving In Friday's Pre-Market Session

TapImmune provided a business and clinical update, wherein it said it plans to advance a Phase 2 Company-sponsored clinical trial in ...

2018-08-24 - Women in England able to take abortion pill at home

... the RCOG to develop clinical guidance that all professionals will be ... campaigning for the change is the Women's Equality Party (WEP).

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$30.1M18915%N/A
#2
$38.5M2128%N/A
#3
$42.8M21329%N/A
#4
$48.2M2171%N/A
#5
$60.7M220-4%N/A